Latest Ratios: P/E Ratio -2.4x · EV/EBITDA N/A · ROE N/A. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $65M | $58M | $37M | $31M | $65M | $252M | $631M | $728M | $618M |
| Enterprise Value | $82M | $74M | $46M | $34M | $79M | $226M | $576M | $722M | $620M |
| P/E Ratio → | -2.39 | — | — | — | — | — | — | — | — |
| P/S Ratio | 326.50 | 289.36 | 107.97 | 47.58 | 137.85 | 349.09 | 3062.35 | — | — |
| P/B Ratio | — | — | — | 2.32 | 20.14 | 20.04 | 1849.99 | 148.89 | 123.56 |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 371.78 | 133.38 | 52.68 | 166.38 | 312.79 | 2795.59 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | 1782.05 |
| EV / EBIT | — | — | — | — | — | — | — | — | 31924.40 |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.5% | 78.5% | 79.5% | 81.5% | 94.5% | 60.0% | 68.4% | — | — |
| Operating Margin | -11541.5% | -11541.5% | -9676.3% | -6198.8% | -10234.5% | -6912.6% | -9812.6% | — | — |
| Net Profit Margin | -13086.5% | -13086.5% | -11520.5% | -7569.4% | -6325.2% | -1347.2% | -9357.8% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -1738.4% | -595.5% | -377.9% | -150.6% | -737.5% | -326.8% | -5.5% |
| ROA | -115.1% | -115.1% | -98.9% | -102.2% | -55.6% | -14.8% | -46.4% | -52.1% | -0.6% |
| ROIC | — | — | -299.7% | -181.7% | -2357.6% | — | — | -379.3% | — |
| ROCE | -189.2% | -189.2% | -150.2% | -140.6% | -110.4% | -88.0% | -60.2% | -56.8% | -0.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 2.40 | 9.83 | 1.91 | 12.68 | 0.59 | 0.64 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 9.26 |
| Net Debt / Equity | — | — | — | 0.25 | 4.17 | -2.08 | -161.15 | -1.21 | 0.50 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 7.13 |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.61 | -8.61 | -8.69 | -9.86 | -8.08 | -10.69 | -18.86 | -182.58 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.83 | 0.83 | 1.57 | 1.53 | 2.11 | 9.06 | 5.40 | 2.20 | 3.56 |
| Quick Ratio | 0.83 | 0.83 | 1.56 | 1.53 | 2.10 | 9.05 | 5.38 | 2.19 | 3.56 |
| Cash Ratio | 0.48 | 0.48 | 1.18 | 1.38 | 1.68 | 8.35 | 5.08 | 2.04 | 3.35 |
| Asset Turnover | — | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | — | — |
| Inventory Turnover | 1.16 | 1.16 | 1.03 | 3.27 | 0.60 | 7.05 | 0.34 | 32.14 | — |
| Days Sales Outstanding | — | — | 417.30 | 746.74 | 2288.77 | 814.31 | 3843.13 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $10M | $7M | $5M | $3M | $3M | $4M | $3M | $3M |
Insolvency and dilutive financing
As reported in recent financial statements, Clene's P/S ratio of 312.32 appears disconnected from fundamental performance, suggesting that the market is pricing the firm based on speculative binary clinical outcomes rather than any tangible revenue-generating capacity or historical valuation norms within the biotechnology sector.
The extreme P/S multiple is a byproduct of a collapsing revenue base rather than high growth expectations, rendering traditional valuation metrics largely meaningless for this entity. Investors should interpret this valuation as a reflection of the market's attempt to assign a probability-weighted value to the CNM-Au8 pipeline, which remains highly uncertain given the company's precarious liquidity position.
Based on the company's reported figures, the ROIC has consistently remained in deeply negative territory, reaching -140.2% in 2025Q3, which underscores a persistent inability to generate returns on invested capital as the firm consumes resources to fund its late-stage clinical development programs.
The negative ROIC trend indicates that every dollar of capital deployed is currently failing to create economic value, a common but severe reality for pre-revenue biotech firms. This decay in capital efficiency warrants further investigation into whether the current clinical trial strategy can ever reach a threshold of profitability that justifies the massive historical capital outlays.
According to the most recent quarterly filings, the current ratio has fluctuated significantly, dropping to 0.83 in 2025Q4, which highlights a deteriorating ability to cover short-term obligations without relying on external financing or further dilution of the existing shareholder base.
The decline in the quick ratio to near-parity with current liabilities suggests that the company has almost no margin for error regarding its operational cash burn. This liquidity profile appears highly vulnerable to any delays in clinical trial milestones or unexpected increases in trial-related expenses, which could force an immediate and potentially dilutive capital raise.
As indicated by historical data, the P/S ratio is the most commonly misapplied metric for Clene, as it obscures the fact that the company's revenue is derived from a legacy supplement business rather than the core clinical-stage biotechnology platform that drives the firm's enterprise value.
Using revenue multiples to value Clene ignores the fundamental reality that the company is essentially a research-driven entity where value is tied to clinical endpoints like NfL reduction rather than product sales. Analysts should instead focus on cash runway and probability-adjusted net present value of the pipeline, as revenue-based metrics provide a false sense of commercial stability.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLNN stock.
Clene Inc.'s current P/E ratio is -2.4x. This places it at the 50th percentile of its historical range.
Based on historical data, Clene Inc. is trading at a P/E of -2.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Clene Inc. has 78.5% gross margin and -11541.5% operating margin.